Stocktoria
Neuronetics, Inc. STIM
Neuronetics, Inc. (STIM) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $149.2M at a -26.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.62 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.219 |
| Retained earnings / assets | -3.241 |
| EBIT / assets | -0.222 |
| Equity / liabilities | 0.228 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| STIM | Neuronetics, Inc. | 4/9 | -10.38 | — | +99.2% |
| INFU | InfuSystem Holdings, Inc | 8/9 | 1.27 | 30.1 | +6.4% |
| XTNT | Xtant Medical Holdings, Inc. | 8/9 | -3.66 | 12.7 | +14.2% |
| HTFL | Heartflow, Inc. | 4/9 | -2.45 | — | +39.9% |
| OSUR | ORASURE TECHNOLOGIES INC | 2/9 | 6.76 | — | -38.1% |
| ANIK | Anika Therapeutics, Inc. | 5/9 | 6.68 | — | -5.9% |
| BBNX | Beta Bionics, Inc. | 4/9 | 6.94 | — | +53.9% |
About Neuronetics, Inc.
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
FAQ
Is STIM financially healthy?
Neuronetics, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does STIM pay a dividend?
No, Neuronetics, Inc. does not currently pay a dividend.
How profitable is STIM?
In FY2025, Neuronetics, Inc. had a net margin of -26.1% and a return on equity of -148.6%.
What is the analyst price target for STIM?
The average Wall-Street price target for Neuronetics, Inc. is $4.33, about 35.0% above the recent price, from 3 analysts.
Is STIM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Neuronetics, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.